In-Depth Study on Major Depressive Disorder - Pipeline Review, H2 2016

Major Depressive Disorder - Pipeline Review, H2 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Major Depressive Disorder (Central Nervous System) pipeline landscape.

Major depressive disorder (MDD) is a mental disorder characterized by a pervasive and persistent low mood that is accompanied by low self-esteem and by a loss of interest or pleasure in normally enjoyable activities. Symptoms of MDD include agitation, restlessness, and irritability, anger, becoming withdrawn or isolated, fatigue and lack of energy, feeling hopeless and helpless, worthless, guilty, self-hate, loss of interest or pleasure in activities that were once enjoyed, sudden change in appetite, often with weight gain or loss, thoughts of death or suicide, trouble concentrating and trouble sleeping or sleeping too much.

Complete report available @ Major Depressive Disorder - Pipeline Review, H2 2016

Report Highlights

This report provides comprehensive information on the therapeutics under development for Major Depressive Disorder (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Major Depressive Disorder (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Major Depressive Disorder and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 8, 18, 11, 1, 8 and 2 respectively for Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively for Major Depressive Disorder.

Major Depressive Disorder (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from a proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Major Depressive Disorder (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Major Depressive Disorder (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Major Depressive Disorder (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Major Depressive Disorder (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Major Depressive Disorder (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Major Depressive Disorder (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Major Depressive Disorder (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned

Aequus Pharmaceuticals Inc. Alkermes Plc Allergan Plc Angelini Group Avanir Pharmaceuticals, Inc. Azevan Pharmaceuticals, Inc. BioCrea GmbH BioLite, Inc. Bristol-Myers Squibb Company Cerecor Inc. Clera Inc. Fabre-Kramer Pharmaceuticals, Inc. GlaxoSmithKline Plc H. Lundbeck A/S Hua Medicine (Shanghai) Ltd. Intra-Cellular Therapies, Inc. Johnson & Johnson Lead Discovery Center GmbH Les Laboratoires Servier SAS Luye Pharma Group Ltd. Mapreg S.A.S. Methylation Sciences Inc. miCure Therapeutics Ltd. Mitsubishi Tanabe Pharma Corporation Neuralstem, Inc. nLife Therapeutics, S.L. Otsuka Holdings Co., Ltd. Pherin Pharmaceuticals, Inc. Reviva Pharmaceuticals Inc. Richter Gedeon Nyrt. Saniona AB Suven Life Sciences Ltd. Takeda Pharmaceutical Company Limited TRImaran Pharma, Inc. Turing Pharmaceuticals AG VistaGen Therapeutics , Inc.

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

ReportstackMarket Research

###